Musculoskeletal disorders, such as rheumatoid arthritis, psoriatic arthritis, lupus, osteoarthritis and juvenile idiopathic arthritis, account for around 20% of all GP consultations in the UK.
The economic impact of these disorders is significant, not only due to the related disability they cause but also due to the cost of biologic treatment or surgery.
The musculoskeletal theme is split into four programmes, with a large focus on using biomarkers to help predict outcomes and personalisation of treatment.
We have a strong track record of musculoskeletal research having had one of only three musculoskeletal NIHR Biomedical Research Units (BRU) previously, which undertook translational clinical research in musculoskeletal disorders.
The BRU pioneered new methods of assessing early response to treatment in adults and children with musculoskeletal disease; new ways of preventing rheumatoid arthritis and its complications; new therapies for arthritis and new resources for patients to help them achieve the best response to treatment. This work forms the basis from which the research described in the BRC musculoskeletal theme is built.